Company Participants
Diane Weiser – Senior Vice President of Corporate Affairs
Robert I. Blum – CEO, President & Director
Fady Malik – Executive Vice President of Research & Development
Stephen Heitner – Senior Vice President of Clinical Research & Development
Stuart Kupfer – Senior VP & Chief Medical Officer
Conference Call Participants
Salim Syed – Mizuho Securities USA LLC, Research Division
Roanna Clarissa Ruiz – Leerink Partners LLC, Research Division
Tessa Romero – JPMorgan Chase & Co, Research Division
Maxwell Skor – Morgan Stanley, Research Division
Mayank Mamtani – B. Riley Securities, Inc., Research Division
Leonid Timashev – RBC Capital Markets, Research Division
Srikripa Devarakonda – Truist Securities, Inc., Research Division
Ashwani Verma – UBS Investment Bank, Research Division
Kyuwon Choi – Goldman Sachs Group, Inc., Research Division
Carter Gould – Cantor Fitzgerald & Co., Research Division
James Condulis – Stifel, Nicolaus & Company, Incorporated, Research Division
Jason Butler – Citizens JMP Securities, LLC, Research Division
Martin Auster – Raymond James & Associates, Inc., Research Division
Cory Kasimov – Evercore ISI Institutional Equities, Research Division
Serge Belanger – Needham & Company, LLC, Research Division
Jason Zemansky – BofA Securities, Research Division
Yanan Zhu – Wells Fargo Securities, LLC, Research Division
Presentation
Operator
Thank you for standing by, and welcome to Cytokinetics’ conference call to discuss the top line results of ACACIA-HCM. This call is being recorded. [Operator Instructions].
I would now like to turn the conference over to Diane Weiser, Cytokinetics’ Senior Vice President of Corporate Affairs. Please go ahead.
Diane Weiser
Senior Vice President of Corporate Affairs
Good morning, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with a brief introduction. Then Fady Malik, EVP of R&D, will provide an overview of the top line data from ACACIA-HCM. Stuart Kupfer, SVP, Chief Medical Officer; and
